01 November 2016

It’s all about access

The UK-based Schistosomiasis Control Initiative (SCI), part of Imperial College London, joined the Pediatric...

SCI advocates to and supports governments to deliver effective school-based and community-based distribution of praziquantel for schistosomiasis and tablets for soil-transmitted helminths, principally protecting children aged between 5-14 years and at-risk adults from these debilitating diseases, all at a cost of US$0.50 or less per child per year.

With SCI’s extensive expertise working with Ministries of Health across sub-Saharan Africa, the Consortium gains support in preparing and implementing the future Access and Delivery plan of the new pediatric formulation of praziquantel in schistosomiasis endemic countries. Treatment of very young children has not been attempted because of the lack of a suitable formulation and SCI is looking forward to assisting the delivery of the new pediatric formulation of praziquantel if the outcome of the clinical trials allows to do so.

The know-how of SCI in deploying preventative and therapeutic tools and strategies to eliminate neglected tropical diseases complements the existing scientific and regulatory expertise provided by the other six partners of the Consortium. Moreover, SCI has a broad network among policy makers including the World Health Organization (WHO), national Ministries of Health, academic institutions, funders and other stakeholders who are all key players in the implementation of an effective awareness and sensitization campaign to increase access to treatment in the coming years.

For more information about SCI, please visit www.imperial.ac.uk/schistosomiasis-control-initiative

Back to newsletter